David G. Hicks
YOU?
Author Swipe
View article: Rapid Malignant Transformation of a Biopsy Proven Sporadic Soft Tissue Schwannoma to Spindle Cell MPNST With <i>TP53</i> Mutation as an Early Event
Rapid Malignant Transformation of a Biopsy Proven Sporadic Soft Tissue Schwannoma to Spindle Cell MPNST With <i>TP53</i> Mutation as an Early Event Open
Malignant peripheral nerve sheath tumors (MPNSTs) primarily originate from the neurofibromatosis 1 (NF1)- associated and/or sporadic neurofibromas. Reports of malignant transformation from a sporadic soft tissue schwannoma are rare. In mos…
View article: Impact of systemic disease on CNS disease control after stereotactic radiosurgery to breast cancer brain metastases (The SYBRA Study)
Impact of systemic disease on CNS disease control after stereotactic radiosurgery to breast cancer brain metastases (The SYBRA Study) Open
The objective of the study is to assess impact of systemic disease (SD) status on overall survival and brain metastasis (BM) control, adopting a novel landmark approach to categorize SD among breast cancer (BC) patients. This single instit…
View article: BMRK-06 BRAIN METASTASIS FREE SURVIVAL OF HER2 LOW AND HER2 ZERO TRIPLE NEGATIVE METASTATIC BREAST CANCER: A WILMOT CANCER INSTITUTE EXPERIENCE (THE HERZELO-TNBC STUDY)
BMRK-06 BRAIN METASTASIS FREE SURVIVAL OF HER2 LOW AND HER2 ZERO TRIPLE NEGATIVE METASTATIC BREAST CANCER: A WILMOT CANCER INSTITUTE EXPERIENCE (THE HERZELO-TNBC STUDY) Open
BACKGROUND It is unclear if level of HER2 expression in metastasis triple negative breast cancer (mTNBC) affects risk of CNS metastasis (CNS-failure). Objective: to compare risk of CNS-failure between HER2-Low [immunohistochemistry 2+ (wit…
View article: Best practices for achieving consensus in <scp>HER2</scp>‐low expression in breast cancer: current perspectives from practising pathologists
Best practices for achieving consensus in <span>HER2</span>‐low expression in breast cancer: current perspectives from practising pathologists Open
Aims Human epidermal growth factor receptor 2 (HER2) expression is an important biomarker in breast cancer (BC). Most BC cases categorised as HER2‐negative (HER2−) express low levels of HER2 [immunohistochemistry (IHC) 1+ or IHC 2+/ in‐sit…
View article: Enhancing the accuracy of shock advisory algorithms in automated external defibrillators during ongoing cardiopulmonary resuscitation using a cascade of CNNEDs
Enhancing the accuracy of shock advisory algorithms in automated external defibrillators during ongoing cardiopulmonary resuscitation using a cascade of CNNEDs Open
Delivery of continuous cardiopulmonary resuscitation (CPR) plays an important role in the out-of-hospital cardiac arrest (OHCA) survival rate. However, to prevent CPR artifacts being superimposed on ECG morphology data, currently available…
View article: Validation and interpretation of Pan-TRK immunohistochemistry: a practical approach and challenges with interpretation
Validation and interpretation of Pan-TRK immunohistochemistry: a practical approach and challenges with interpretation Open
Objectives Actionable, solid tumor activating neurotrophic receptor tyrosine kinase ( NTRK ) fusions are best detected via nucleic acid-based assays, while Pan-TRK immunohistochemistry (IHC) serves as a reasonable screening modality. We de…
View article: Analytical and clinical validation of PATHWAY Anti-HER-2/neu (4B5) antibody to assess HER2-low status for trastuzumab deruxtecan treatment in breast cancer
Analytical and clinical validation of PATHWAY Anti-HER-2/neu (4B5) antibody to assess HER2-low status for trastuzumab deruxtecan treatment in breast cancer Open
In DESTINY-Breast04 (DB-04), safety and efficacy of HER2-targeted antibody-drug conjugate (ADC) trastuzumab deruxtecan (T-DXd) in previously treated HER2-low unresectable/metastatic breast cancer were established. This manuscript describes…
View article: HER2 in uterine serous carcinoma: Current state and clinical perspectives
HER2 in uterine serous carcinoma: Current state and clinical perspectives Open
Objectives Uterine cancer has the highest incidence and the second-highest mortality rate among gynecologic malignancies in the United States. Although uterine serous carcinoma (USC) represents less than 10% of endometrial carcinomas, it a…
View article: Exploration of HER2 (ERBB2) immunohistochemistry in non-small cell lung cancer: correlation with ERBB2 mutational status: experimental research
Exploration of HER2 (ERBB2) immunohistochemistry in non-small cell lung cancer: correlation with ERBB2 mutational status: experimental research Open
ERBB2 ( HER2 ) is a gene in humans that encodes the ERBB2 protein, a member of the epidermal growth factor receptor family. Non-small cell lung carcinomas do not commonly harbour ERBB2 mutations, with clinical trials conducted to assess fo…
View article: Emerging Landscape of Targeted Therapy of Breast Cancers With Low Human Epidermal Growth Factor Receptor 2 Protein Expression
Emerging Landscape of Targeted Therapy of Breast Cancers With Low Human Epidermal Growth Factor Receptor 2 Protein Expression Open
Context.— Human epidermal growth factor receptor 2 (HER2) status in breast cancer is currently classified as negative or positive for selecting patients for anti-HER2 targeted therapy. The evolution of the HER2 status has included a new HE…
View article: Supplementary Figure 1 from Heat Shock Protein 27 Differentiates Tolerogenic Macrophages That May Support Human Breast Cancer Progression
Supplementary Figure 1 from Heat Shock Protein 27 Differentiates Tolerogenic Macrophages That May Support Human Breast Cancer Progression Open
Supplementary Figure 1 from Heat Shock Protein 27 Differentiates Tolerogenic Macrophages That May Support Human Breast Cancer Progression
View article: Supplementary Figure 2 from Heat Shock Protein 27 Differentiates Tolerogenic Macrophages That May Support Human Breast Cancer Progression
Supplementary Figure 2 from Heat Shock Protein 27 Differentiates Tolerogenic Macrophages That May Support Human Breast Cancer Progression Open
Supplementary Figure 2 from Heat Shock Protein 27 Differentiates Tolerogenic Macrophages That May Support Human Breast Cancer Progression
View article: Supplementary Figure Legends 1-2 from Heat Shock Protein 27 Differentiates Tolerogenic Macrophages That May Support Human Breast Cancer Progression
Supplementary Figure Legends 1-2 from Heat Shock Protein 27 Differentiates Tolerogenic Macrophages That May Support Human Breast Cancer Progression Open
Supplementary Figure Legends 1-2 from Heat Shock Protein 27 Differentiates Tolerogenic Macrophages That May Support Human Breast Cancer Progression
View article: Supplementary Figure 2 from Heat Shock Protein 27 Differentiates Tolerogenic Macrophages That May Support Human Breast Cancer Progression
Supplementary Figure 2 from Heat Shock Protein 27 Differentiates Tolerogenic Macrophages That May Support Human Breast Cancer Progression Open
Supplementary Figure 2 from Heat Shock Protein 27 Differentiates Tolerogenic Macrophages That May Support Human Breast Cancer Progression
View article: Supplementary Figure Legends 1-2 from Heat Shock Protein 27 Differentiates Tolerogenic Macrophages That May Support Human Breast Cancer Progression
Supplementary Figure Legends 1-2 from Heat Shock Protein 27 Differentiates Tolerogenic Macrophages That May Support Human Breast Cancer Progression Open
Supplementary Figure Legends 1-2 from Heat Shock Protein 27 Differentiates Tolerogenic Macrophages That May Support Human Breast Cancer Progression
View article: Data from Heat Shock Protein 27 Differentiates Tolerogenic Macrophages That May Support Human Breast Cancer Progression
Data from Heat Shock Protein 27 Differentiates Tolerogenic Macrophages That May Support Human Breast Cancer Progression Open
Tumor cells release several factors that can help the progression of the tumor by directly supporting tumor growth and/or suppressing host antitumor immunity. Here, we report that human primary breast tumor cells not only express elevated …
View article: Data from Heat Shock Protein 27 Differentiates Tolerogenic Macrophages That May Support Human Breast Cancer Progression
Data from Heat Shock Protein 27 Differentiates Tolerogenic Macrophages That May Support Human Breast Cancer Progression Open
Tumor cells release several factors that can help the progression of the tumor by directly supporting tumor growth and/or suppressing host antitumor immunity. Here, we report that human primary breast tumor cells not only express elevated …
View article: Supplementary Figure 1 from Heat Shock Protein 27 Differentiates Tolerogenic Macrophages That May Support Human Breast Cancer Progression
Supplementary Figure 1 from Heat Shock Protein 27 Differentiates Tolerogenic Macrophages That May Support Human Breast Cancer Progression Open
Supplementary Figure 1 from Heat Shock Protein 27 Differentiates Tolerogenic Macrophages That May Support Human Breast Cancer Progression
View article: Interobserver and Interantibody Reproducibility of HER2 Immunohistochemical Scoring in an Enriched HER2-Low–Expressing Breast Cancer Cohort
Interobserver and Interantibody Reproducibility of HER2 Immunohistochemical Scoring in an Enriched HER2-Low–Expressing Breast Cancer Cohort Open
Objectives We assessed the interobserver and interantibody reproducibility of HER2 immunohistochemical scoring in an enriched HER2-low–expressing breast cancer cohort. Methods A total of 114 breast cancer specimens were stained by HercepTe…
View article: The Rochester Modified Magee Algorithm (RoMMa): An Outcomes Based Strategy for Clinical Risk-Assessment and Risk-Stratification in ER Positive, HER2 Negative Breast Cancer Patients Being Considered for Oncotype DX® Testing
The Rochester Modified Magee Algorithm (RoMMa): An Outcomes Based Strategy for Clinical Risk-Assessment and Risk-Stratification in ER Positive, HER2 Negative Breast Cancer Patients Being Considered for Oncotype DX® Testing Open
Introduction: Multigene genomic profiling has become the standard of care in the clinical risk-assessment and risk-stratification of ER+, HER2− breast cancer (BC) patients, with Oncotype DX® (ODX) emerging as the genomic profile test with …
View article: The Evolution of Ki-67 and Breast Carcinoma: Past Observations, Present Directions, and Future Considerations
The Evolution of Ki-67 and Breast Carcinoma: Past Observations, Present Directions, and Future Considerations Open
The 1983 discovery of a mouse monoclonal antibody—the Ki-67 antibody—that recognized a nuclear antigen present only in proliferating cells represented a seminal discovery for the pathologic assessment of cellular proliferation in breast ca…
View article: Using Health Care Professionals’ Perspectives to Refine a Clinical Decision Support Implementation Strategy for Increasing the Prescribing of HIV Preexposure Prophylaxis (PrEP) in Alabama
Using Health Care Professionals’ Perspectives to Refine a Clinical Decision Support Implementation Strategy for Increasing the Prescribing of HIV Preexposure Prophylaxis (PrEP) in Alabama Open
Pre-exposure prophylaxis (PrEP) is underused in the southern United States (US), a region with high HIV incidence. Clinical decision support (CDS) tools could increase PrEP prescriptions. We explored barriers to PrEP delivery and views of …
View article: Biomarker and multigene assay testing in ER positive, HER-2 negative breast carcinomas: An international guidelines-based approach
Biomarker and multigene assay testing in ER positive, HER-2 negative breast carcinomas: An international guidelines-based approach Open
As breast cancer treatment options continue to evolve, biomarker and multigene assay testing are now considered a standard part of the clinical evaluation of estrogen receptor (ER) positive, human epidermal growth factor receptor 2 (HER-2)…
View article: Vascular lesions of the breast: Essential pathologic features and diagnostic pitfalls
Vascular lesions of the breast: Essential pathologic features and diagnostic pitfalls Open
Vascular lesions are uncommonly encountered in the breast and they represent a spectrum of benign, atypical and malignant entities. The mammary angiosarcomas can be primary arising de novo, or most frequently secondary to prior radiation t…
View article: HER2-Low Breast Cancers
HER2-Low Breast Cancers Open
Objectives Recent clinical trials have demonstrated significant clinical benefits from novel therapeutic compounds in breast cancer patient with human epidermal growth factor receptor 2 (HER2) immunohistochemical (IHC) score of 1+ or 2+ an…
View article: Pathologists at the Leading Edge of Optimizing the Tumor Tissue Journey for Diagnostic Accuracy and Molecular Testing
Pathologists at the Leading Edge of Optimizing the Tumor Tissue Journey for Diagnostic Accuracy and Molecular Testing Open
Objectives Tumor biomarker analyses accompanying immuno-oncology therapies are coupled with a tumor tissue journey aiming to guide tissue procurement and allow for accurate diagnosis and delivery of test results. The engagement of patholog…
View article: Significance of HER2 in Microinvasive Breast Carcinoma
Significance of HER2 in Microinvasive Breast Carcinoma Open
Objectives We compared the clinicopathologic features, clinical management, and outcomes of human epidermal growth factor receptor 2 (HER2)–expressing and nonexpressing microinvasive breast carcinomas (MiBC) to explore the significance of …
View article: L1CAM Expression in Recurrent Estrogen Positive/HER2 Negative Breast Cancer
L1CAM Expression in Recurrent Estrogen Positive/HER2 Negative Breast Cancer Open
Background: We investigate L1CAM expression in ER positive/HER2 negative breast carcinomas. The finding of a potential correlation between high L1CAM expression and recurrent/metastatic disease in luminal A and B breast carcinomas may be h…